Advisor Group Holdings, Inc. Contrafect Corp Transaction History

Advisor Group Holdings, Inc.

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$0.18 - $3.51 $36 - $702	-200 Reduced 66.67%	100 $0
Q1 2022 May 04, 2022	BUY	$2.26 - $3.84 $225 - $384	100 Added 50.0%	300 $1,000
Q1 2020 May 18, 2020	BUY	$5.5 - $12.3 $1,100 - $2,460	200 New	200 $1,000

49.2K

Ticker CFRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,332,700
Market Cap $1.18M
Description
ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus...

Get notified when there are updates to the investment portfolio of Advisor Group Holdings, Inc., based on Form 13F filings with the SEC.

Stay updated on Advisor Group Holdings, Inc. with notifications on news.